Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol

被引：83
|
作者：
Garg, Satish K. [1 ,2 ]
Peters, Anne L. [3 ]
Buse, John B. [4 ]
Danne, Thomas [5 ]
机构：
[1] Univ Colorado Denver, Sch Med, Dept Med & Pediat, Aurora, CO USA
[2] Barbara Davis Ctr Diabet, Aurora, CO USA
[3] Univ Southern Calif, Keck Sch Med, Los Angeles, CA USA
[4] Univ N Carolina, Sch Med, Chapel Hill, NC 27515 USA
[5] Hannover Med Sch, Childrens & Youth Hosp Bult, Hannover, Germany
来源：
DIABETES TECHNOLOGY & THERAPEUTICS | 2018年 / 20卷 / 09期
关键词：
INSULIN; KETOACIDOSIS; DAPAGLIFLOZIN; CHILDREN; STATE;
D O I：
10.1089/dia.2018.0246
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：571 / 575
页数：5
相关论文
共 50 条
  • [1] Commentary: SGLT inhibitors in type 1 diabetes: Place in therapy and a risk mitigation strategy for preventing diabetic ketoacidosis - the STOP DKA protocol
    Rendell, Marc S.
    DIABETES OBESITY & METABOLISM, 2019, 21 (10): : 2189 - 2191
  • [2] SGLT inhibition: a possible adjunctive treatment for type 1 diabetes
    Akturk, Halis Kaan
    Rewers, Amanda
    Garg, Satish K.
    CURRENT OPINION IN ENDOCRINOLOGY DIABETES AND OBESITY, 2018, 25 (04) : 246 - 250
  • [3] SGLT-2 inhibitors as adjunctive to insulin therapy in type 1 diabetes
    Maj-Podsiadlo, Anna
    Cichocka, Edyta
    Gumprecht, Janusz
    CLINICAL DIABETOLOGY, 2020, 9 (03): : 189 - 192
  • [4] Sodium-glucose co-transporter inhibitors, their role in type 1 diabetes treatment and a risk mitigation strategy for preventing diabetic ketoacidosis: The STOP DKA Protocol
    Goldenberg, Ronald M.
    Gilbert, Jeremy D.
    Hramiak, Irene M.
    Woo, Vincent C.
    Zinman, Bernard
    DIABETES OBESITY & METABOLISM, 2019, 21 (10): : 2192 - 2202
  • [5] SGLT inhibitors for type 1 diabetes
    Das, Gautam
    PRACTICAL DIABETES, 2020, 37 (03) : 82 - 85
  • [6] SGLT2 inhibitors as adjunctive therapy for type 1 diabetes: balancing benefits and risks
    Taylor, Simeon I.
    Blau, Jenny E.
    Rother, Kristina I.
    Beitelshees, Amber L.
    LANCET DIABETES & ENDOCRINOLOGY, 2019, 7 (12): : 949 - 958
  • [7] EXPERIENCE WITH RISK MITIGATION USING SGLT INHIBITORS IN TYPE 1 DIABETES
    Danne, T.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2020, 22 : A6 - A7
  • [8] SGLT INHIBITORS FOR TYPE 1 DIABETES - INTRODUCTION
    Garg, S.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2020, 22 : A5 - A6
  • [9] SGLT inhibitors for people with type 1 diabetes
    Llano, Andrea
    McKay, Gerry
    Fisher, Miles
    PRACTICAL DIABETES, 2019, 36 (03) : 91 - 96
  • [10] The efficacy and safety of SGLT2 inhibitors for adjunctive treatment of type 1 diabetes: a systematic review and meta-analysis
    Jiao Chen
    Fang Fan
    J. Y. Wang
    Yang Long
    C. L. Gao
    R. C. Stanton
    Yong Xu
    Scientific Reports, 7
12345